CD4 and pancreatic ductal adenocarcinoma: In addition, anti- PD-1 immunotherapy manipulated CD4+ T cell chemotaxis response by reshaping CD11b+ neutrophil degranulation activity, which was considered a clinical indicator of successful pancreatic ductal adenocarcinoma (PDAC) immunotherapy [26].